Answers are grounded in this paper and cite their sources.
Combination therapy with avelumab and cetuximab improves outcomes in advanced cutaneous squamous cell carcinoma, suggesting a new approach against pd-1 blockade resistance.
Journal Article Accepted manuscript Avelumab plus cetuximab in advanced cutaneous squamous cell carcinoma: a strategy to overcome resistance to PD-1 blockade Get access Eve Maubec Eve Maubec Department of Dermatology, Avicenne University Hospital, AP-HP, Sorbonne Paris Nord University, Bobigny, FranceINSERM UMR1124, Paris Cité University, Paris, France Correspondence: Eve Maubec., Email: [email protected] https://orcid.org/0000-0003-1658-6686 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljaf331, https://doi.org/10.1093/bjd/ljaf331 Published: 21 August 2025 Article history Received: 17 August 2025 Accepted: 18 August 2025 Published: 21 August 2025
No takes yet. Share an insight, caveat, or question.
E. Maubec (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: